FDA
-
-
-
-
-
-
-
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI
-
-
-
-
-
-
-
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025
-
-
-
-
-
-
-
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025
-
-
-
-
-
-
-
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering
-
-
-
-
-
-
-
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
-
-
-
-
-
-
-
Revelation Biosciences (REVB) Announces Exercise of Warrants for $4 Million in Gross Proceeds
-
-
-
-
-
-
-
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

